Sun Pharma Signs a License Agreement with Rockwell Medical for Triferic in India

 Sun Pharma Signs a License Agreement with Rockwell Medical for Triferic in India

Sun Pharma Signs a License Agreement with Rockwell Medical for Triferic in India

Shots:

  • Rockwell to receive up front, milestones and royalties on sales of Triferic. Sun Pharma to get an exclusive right to develop & commercialize Triferic, following its approval in India
  •  Sun Pharma will be responsible for all clinical, regulatory and commercialization activities of Triferic in India. The collaboration allows Sun Pharma to expand its portfolio in its core therapy areas
  • Rockwell’s Triferic is a US FDA approved therapy indicated to replace iron and maintain hemoglobin in hemodialysis patients via dialysate during each dialysis treatment

Click here ­to­ read full press release/ article | Ref: Sun Pharma | Image: Behance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post